Complementary and alternative medicine use in patients with haematological malignancies in Europe

Alexander Molassiotis, Anita Margulies, Paz Fernandez-Ortega, Dorit Pud, Vassiliki Panteli, Ingrid Bruyns, Julia A. Scott, Gudbjorg Gudmundsdottir, Maria Browall, Elin Madsen, Gulten Ozden, Miriam Magri, Sarka Selvekerova, Nurgun Platin, Nora Kearney, Elisabeth Patiraki

Research output: Contribution to journalArticlepeer-review


This study reports upon a descriptive cross-sectional survey assessing the use of complementary and alternative medicine (CAM) in patients with haematological cancers. Twelve European countries contributed data from patients with haematological cancers, as part of a larger study. Sixty-eight patients with haematological cancer participated. Among the participants, 26.5% used some form of CAM after the cancer diagnosis. The most common therapies used were homeopathy (38.9%), herbal medicine (22.2%) various psychic therapies, such as use of mediums, healers, rebirthing or past life regression therapy (22.2%). A particular profile of a CAM user was not evident in the sample. Moderate levels of satisfaction with CAM were reported. Patients commonly used CAM to increase the ability of their body to fight cancer and to improve physical and emotional well-being. Information about CAM was received mainly from friends or family. As CAM use in patients with haematological malignancies is common, clinicians should assist patients who want to use CAM to make an appropriate decision, and improve communication with them about CAM use in an open and non-judgemental dialogue.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalComplementary Therapies in Clinical Practice
Issue number2
StatePublished - May 2005


  • Alternative medicine
  • Complementary medicine
  • Complementary therapies
  • Haematologic cancers
  • Leukaemia
  • Lymphoma
  • Myeloma

ASJC Scopus subject areas

  • Complementary and alternative medicine


Dive into the research topics of 'Complementary and alternative medicine use in patients with haematological malignancies in Europe'. Together they form a unique fingerprint.

Cite this